Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Last trade$0.3081
Day change-$0.0614 (-16.62%)
Day range$0.304 – $0.426
Volume1,362,268
Market cap$69M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$69.52M
Price / earnings
—
Price / book
1.56×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.03×
Profitability
Earnings per share
-$1.13
Return on assets
-169.86%
Return on equity
-477.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.19×
Current ratio
4.5×
Quick ratio
4.5×
Cash ratio
4.21×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$180.52M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NMRA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$12.91M
$14.27M
$13.81M
$12.18M
$15.32M
$18.79M
$17.01M
$16.02M
Research and development
$29.28M
$38.6M
$44.67M
$45.52M
$38.72M
$52.15M
$45.91M
$60.63M
Total operating expenses
$42.19M
$52.86M
$58.48M
$57.7M
$54.04M
$70.94M
$62.92M
$76.65M
Operating income
-$42.19M
-$52.86M
-$58.48M
-$57.7M
-$54.04M
-$70.94M
-$62.92M
-$76.65M
Interest expense
-$1.82M
-$1.85M
-$2.04M
-$747K
-$436K
$0
$0
$0
Income before taxes
-$43.08M
-$53.43M
-$59.45M
-$56.76M
-$52.71M
-$67.89M
-$58.82M
-$72.49M
Income taxes
$0
$30K
$0
$0
$25K
$105K
$0
$53K
Net income
-$43.08M
-$53.46M
-$59.45M
-$56.76M
-$52.73M
-$67.99M
-$58.82M
-$72.55M
Net income attributable to common shareholders
-$43.08M
-$53.46M
-$59.45M
-$56.76M
-$52.73M
-$68.06M
-$58.82M
-$72.55M
EBITDA
-$42.18M
-$52.86M
-$58.47M
-$57.68M
-$54.02M
-$70.78M
-$62.77M
-$76.49M
Basic earnings per share
-$0.23
-$0.30
-$0.35
-$0.35
-$0.33
-$0.42
-$0.37
-$0.45
Diluted earnings per share
-$0.23
-$0.30
-$0.35
-$0.35
-$0.33
-$0.42
-$0.37
-$0.45
Recent news
Company coverage with links to the original publishers.
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to achieve primary endpoints for major depressive disorder treatment, leading the company to discontinue the program. The company is refocusing on three other clinical programs (NMRA-511, NMRA-898, and NMRA-215) and implementing a 35% workforce reduction to extend cash runway into Q3 2027.
The Schall Law Firm is investigating Neumora Therapeutics, Inc. (NASDAQ: NMRA) on behalf of investors for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.
Neumora Therapeutics announced it will host a conference call on March 30, 2026, to report Q4 and full year 2025 financial results and provide a business update. The clinical-stage biopharmaceutical company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including consolidated topline readouts for KOASTAL-2 and -3 trials anticipated in Q2 2026.
Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including KOASTAL-2 and -3 trials anticipated for Q2 2026 readout. Additionally, positive Phase 1b results from NMRA-511 in Alzheimer's disease agitation showed a clinically meaningful 15.7-point reduction on the CMAI total score.
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.